Giorgio Corti

Giorgio Corti

Auto-generated profile, based on publicly available information

Giorgio Corti

Candiolo Cancer Institute, FPO - IRCCS, Candiolo, Torino, Italy

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2015 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
Giulia SiravegnaGiulia Siravegna
Giulia Siravegna
BMBenedetta Mussolin
Benedetta Mussolin
MBMichela Buscarino
Michela Buscarino
GCGiorgio Corti
Giorgio Corti
ACAndrea Cassingena
Andrea Cassingena
ABAlberto Bardelli
Alberto Bardelli

1 June 2013 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
ABAlberto Bardelli
Alberto Bardelli
Simona CorsoSimona Corso
Simona Corso
ABAndrea Bertotti
Andrea Bertotti
SHSebastijan Hobor
Sebastijan Hobor
EVEmanuele Valtorta
Emanuele Valtorta
SSSalvatore Siena
Salvatore Siena
EGF receptor (EGFR)-targeted monoclonal antibodies are effective in a subset of metastatic colorectal cancers. Inevitably, all patients develop resistance, which occurs through emergence of KRAS mutations in approximately 50% of the cases. We show that amplification of the MET proto-oncogene is associated with acquired resistance in tumors that do not develop KRAS mutations during anti-EGFR therapy. Amplification of the MET locus was present in circulating tumor DNA before relapse was clinically evident. Functional studies show that MET activation confers resistance to anti-EGFR therapy both in vitro and in vivo. Notably, in patient-derived colorectal cancer xenografts, MET amplification correlated with resistance to EGFR blockade, which could be overcome by MET kinase inhibitors. These results highlight the role of MET in mediating primary and secondary resistance to anti-EGFR therapies in colorectal cancer and encourage the use of MET inhibitors in patients displaying resistance as a result of MET amplification. Significance: Amplification of the MET proto-oncogene is responsible for de novo and acquired resistance to anti-EGFR therapy in a subset of colorectal cancers. As multiple anti-MET therapeutic strategies are available, these findings offer immediate novel opportunities to design clinical studies. Cancer Discov; 3(6); 658–73. ©2013 AACR. This article is highlighted in the In This Issue feature, p. 591

1 February 2016 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
Mariangela RussoMariangela Russo
Mariangela Russo
Giulia SiravegnaGiulia Siravegna
Giulia Siravegna
LBLawrence S. Blaszkowsky
Lawrence S. Blaszkowsky
GCGiorgio Corti
Giorgio Corti
Giovanni CrisafulliGiovanni Crisafulli
Giovanni Crisafulli
RCRyan B. Corcoran
Ryan B. Corcoran
How genomic heterogeneity associated with acquired resistance to targeted agents affects response to subsequent therapy is unknown. We studied EGFR blockade in colorectal cancer to assess whether tissue and liquid biopsies can be integrated with radiologic imaging to monitor the impact of individual oncogenic alterations on lesion-specific responses. Biopsy of a patient's progressing liver metastasis following prolonged response to cetuximab revealed a MEK1K57T mutation as a novel mechanism of acquired resistance. This lesion regressed upon treatment with panitumumab and the MEK inhibitor trametinib. In circulating tumor DNA (ctDNA), mutant MEK1 levels declined with treatment, but a previously unrecognized KRASQ61H mutation was also identified that increased despite therapy. This same KRAS mutation was later found in a separate nonresponding metastasis. In summary, parallel analyses of tumor biopsies and serial ctDNA monitoring show that lesion-specific radiographic responses to subsequent targeted therapies can be driven by distinct resistance mechanisms arising within separate tumor lesions in the same patient. Significance: Molecular heterogeneity ensuing from acquired resistance drives lesion-specific responses to subsequent targeted therapies. Analysis of a single-lesion biopsy is inadequate to guide selection of subsequent targeted therapies. ctDNA profiles allow the detection of concomitant resistance mechanisms residing in separate metastases and assessment of the effect of therapies designed to overcome resistance. Cancer Discov; 6(2); 147–53. ©2015 AACR. See related commentary by Hiley and Swanton, p. 122. This article is highlighted in the In This Issue feature, p. 109

1 January 2016 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
Mariangela RussoMariangela Russo
Mariangela Russo
SMSandra Misale
Sandra Misale
GWGe Wei
Ge Wei
Giulia SiravegnaGiulia Siravegna
Giulia Siravegna
Giovanni CrisafulliGiovanni Crisafulli
Giovanni Crisafulli
ABAlberto Bardelli
Alberto Bardelli
Entrectinib is a first-in-class pan-TRK kinase inhibitor currently undergoing clinical testing in colorectal cancer and other tumor types. A patient with metastatic colorectal cancer harboring an LMNA–NTRK1 rearrangement displayed a remarkable response to treatment with entrectinib, which was followed by the emergence of resistance. To characterize the molecular bases of the patient's relapse, circulating tumor DNA (ctDNA) was collected longitudinally during treatment, and a tissue biopsy, obtained before entrectinib treatment, was transplanted in mice (xenopatient), which then received the same entrectinib regimen until resistance developed. Genetic profiling of ctDNA and xenopatient samples showed acquisition of two point mutations in the catalytic domain of NTRK1, p.G595R and p.G667C. Biochemical and pharmacologic analysis in multiple preclinical models confirmed that either mutation renders the TRKA kinase insensitive to entrectinib. These findings can be immediately exploited to design next-generation TRKA inhibitors. Significance: We provide proof of principle that analyses of xenopatients (avatar) and liquid biopsies allow the identification of drug resistance mechanisms in parallel with clinical treatment of an individual patient. We describe for the first time that p.G595R and p.G667C TRKA mutations drive acquired resistance to entrectinib in colorectal cancers carrying NTRK1 rearrangements. Cancer Discov; 6(1); 36–44. ©2015 AACR. See related commentary by Okimoto and Bivona, p. 14. This article is highlighted in the In This Issue feature, p. 1

30 April 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
EMEnzo Medico
Enzo Medico
Mariangela RussoMariangela Russo
Mariangela Russo
GPGabriele Picco
Gabriele Picco
CCCarlotta Cancelliere
Carlotta Cancelliere
EVEmanuele Valtorta
Emanuele Valtorta
ABAlberto Bardelli
Alberto Bardelli
The development of molecularly targeted anticancer agents relies on large panels of tumour-specific preclinical models closely recapitulating the molecular heterogeneity observed in patients. Here we describe the mutational and gene expression analyses of 151 colorectal cancer (CRC) cell lines. We find that the whole spectrum of CRC molecular and transcriptional subtypes, previously defined in patients, is represented in this cell line compendium. Transcriptional outlier analysis identifies RAS/BRAF wild-type cells, resistant to EGFR blockade, functionally and pharmacologically addicted to kinase genes including ALK, FGFR2, NTRK1/2 and RET. The same genes are present as expression outliers in CRC patient samples. Genomic rearrangements (translocations) involving the ALK and NTRK1 genes are associated with the overexpression of the corresponding proteins in CRC specimens. The approach described here can be used to pinpoint CRCs with exquisite dependencies to individual kinases for which clinically approved drugs are already available.

30 April 2015 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
SASabrina Arena
Sabrina Arena
BBBeatriz Bellosillo
Beatriz Bellosillo
Giulia SiravegnaGiulia Siravegna
Giulia Siravegna
AMAlejandro Martínez
Alejandro Martínez
ICIsrael Cañadas
Israel Cañadas
CMClara Montagut
Clara Montagut
Purpose: Patients with colorectal cancer who respond to the anti-EGFR antibody cetuximab often develop resistance within several months of initiating therapy. To design new lines of treatment, the molecular landscape of resistant tumors must be ascertained. We investigated the role of mutations in the EGFR signaling axis on the acquisition of resistance to cetuximab in patients and cellular models. Experimental Design: Tissue samples were obtained from 37 patients with colorectal cancer who became refractory to cetuximab. Colorectal cancer cells sensitive to cetuximab were treated until resistant derivatives emerged. Mutational profiling of biopsies and cell lines was performed. Structural modeling and functional analyses were performed to causally associate the alleles to resistance. Results: The genetic profile of tumor specimens obtained after cetuximab treatment revealed the emergence of a complex pattern of mutations in EGFR, KRAS, NRAS, BRAF, and PIK3CA genes, including two novel EGFR ectodomain mutations (R451C and K467T). Mutational profiling of cetuximab-resistant cells recapitulated the molecular landscape observed in clinical samples and revealed three additional EGFR alleles: S464L, G465R, and I491M. Structurally, these mutations are located in the cetuximab-binding region, except for the R451C mutant. Functionally, EGFR ectodomain mutations prevent binding to cetuximab but a subset is permissive for interaction with panitumumab. Conclusions: Colorectal tumors evade EGFR blockade by constitutive activation of downstream signaling effectors and through mutations affecting receptor–antibody binding. Both mechanisms of resistance may occur concomitantly. Our data have implications for designing additional lines of therapy for patients with colorectal cancer who relapse upon treatment with anti-EGFR antibodies. Clin Cancer Res; 21(9); 2157–66. ©2015 AACR.